Technology Bundle ID: TAB-2854

Inhibition of HIV Infection through Chemoprophylaxis Using Emtricitabine and Tenofovir

Request More Info
Licensing Contact:
Primary Inventors: 
Walid Heneine (CDC)
Jose Garcia Lerma (CDC), Robert Janssen (CDC), Ronald Otten (CDC), Thomas Folks (CDC)
Development Stage: 
Pre-clinical (in vivo)
Development Status: 
  • In vivo data available (animal)
  • In vivo data available (human)
Institute or Center: 

The invention is directed to prophylactic administration of emtricitabine (FTC) in combination with tenofovir or its prodrug, tenofovir disoproxil fumarate (TDF), to protect against transmission of human immunodeficiency virus (HIV) infection. Also disclosed are other nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) that, when administered in combination, protect against HIV infection. CDC researchers demonstrated that daily pre-exposure prophylaxis (PrEP) with a combination of antiretroviral NRTI and NtTRI drugs, including FTC and TDF, significantly increases the level of protection against HIV transmission.

  • Oral, prophylactic delivery of combination drugs to inhibit HIV infection


PCT Application PCT/US2007/002926
Filed on 2007-02-01
US Application 16/413,381
Filed on 2019-05-15
US Application 16/808,089
Filed on 2020-03-03
US Application 16/808,120
Filed on 2020-03-03
US Application 16/808,135
Filed on 2020-03-03
US Application 17/170,535
Filed on 2021-02-08
US Application 17/186,534
Filed on 2021-02-26
US Application 17/186,559
Filed on 2021-02-26
US Application 17/186,583
Filed on 2021-02-26
US Application 60/764,811
Filed on 2006-02-03
US Pat 10,335,423

Issued 2019-07-02
US Pat 9,044,509

Issued 2015-06-02
US Pat 9,579,333

Issued 2017-02-28
US Pat 9,937,191

Issued 2018-04-10

and various international issued patents/pending applications


Garcia-Lerma J, et al.
PMID 18254653
Garcia-Lerma J, et al.
PMID 20371467


Sep 9, 2014

Data Source: